Skip to main content

Table 2 Performance of line probe assay (LPA) in detecting rifampicin, isoniazid and multidrug-resistance from smear-positive sputum specimens

From: Rapid screening of MDR-TB using molecular Line Probe Assay is feasible in Uganda

  Rifampicin Isoniazid Multi-drug resistance Rifampicin as predictor of MDR
No. resistant/No. susceptible strains 15/77 26/66 13/79 13/79
Sensitivity, %
(95% CI)
100.0%
(78.2 - 100.0)*
80.8%
(60.6 - 93.4)
92.3%
(64.0 - 99.8)
100.0%
(75.3-100.0)*
Specificity, %
(95% CI)
96.1%
(89.0 - 99.2)
100.0%
(94.5 - 100.0)*
96.2%
(89.3 - 99.2)
96.2%
(89.3 - 99.2)
Overall accuracy, % (95% CI) 96.7%
(90.8 - 99.3)
94.6
(87.8 - 98.2)
95.7%
(89.2 - 98.8)
96.7%
(90.7 - 99.3)
PPV, %
(95% CI)
83.3%
(58.6 - 96.4)
100.0%
(83.9 - 100.0) *
80.0%
(51.9 - 95.7)
81.3%
(54.3 - 96.0)
NPV, %
(95% CI)
100.0%
(95.1 - 100.0)
93.0%
(84.3 - 97.7)
98.7%
(92.9 - 100.0)
100.0%
(95.3 - 100.0)*
  1. * one-sided, 97.5% confidence interval